Dilated Cardiomyopathy (DCM)
19
9
10
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 19 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (19)
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
BAG3-DCM Natural History Study
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
Study of the Progression of Chronic Cardiovascular Conditions
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Multimodal Analysis of Endomyocardial Biopsies
The Application of T1 Mapping in Real-World
Mainstreaming Genetic Testing for Non-Ischemic Cardiomyopathy in Western Canada
Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy
UIC Multi-Ethnic DCM Registry
Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)
Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy
Early Identification and Treatment of Rare Cardiomyopathy Cohorts
AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA
Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study